Non Alcoholic Fatty Liver Disease Influence of Statin Therapy

Non-alcoholic Fatty Liver Disease (NAFLD) Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00375349
• Other study ID #: 20173CTIL
• Status: Withdrawn
• Phase: N/A
• First received: September 11, 2006
• Last updated: September 29, 2016
• Start date: September 2006
• Est. completion date: September 2009

Study information

• Verified date: September 2016
• Source: Shaare Zedek Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

Aim:

1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department.

2. To assess the effect of statins on the prevalence of fatty liver by a cross sectional survey of patients hospitalized with chest pain.

Description:

Consecutive patients hospitalized with chest pain will be recruited at the cardiology department. Patients with an inflammatory condition, recent infection or history of alcoholism will be excluded. After signing an informed consent each patient will undergo an ultrasound examination for diagnosis of fatty liver. Information regarding BMI, hypertension and use of medications will be collected on each patient. Blood samples for fasting glucose, hemoglobin A1C, lipid profile, ESR, and CRP and liver function tests will be collected from each participant. Prevalence of fatty liver in patients who have been taking statins for 6 months or more statins will be compared to patients who have been taking statins for a lesser period and to those who do have not taken statins using a multivariate regression analysis.

Serum samples will be frozen and kept for future ongoing research.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Cardiology patient

• Age above 18

Exclusion Criteria:

• Age below 18

Study Design

N/A

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Fatty Liver Disease (NAFLD)

Intervention

Procedure:
• Ultrasound to demonstrate existence of fatty liver

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shaare Zedek Medical Center

References & Publications (1)

Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006 Jan;184(1):233-4. Epub 2005 Oct 5. — View Citation